Novartis AG
LPL-GPIHBP1 FUSION POLYPEPTIDES

Abstract:

This disclosure relates to fusion polypeptides comprising lipoprotein lipase (LPL) and glycosylphosphatidylinositol-anchored High Density Lipoprotein-binding protein 1 (GPIHBP1). The disclosure also relates to uses of such fusion polypeptides in treating disease such as familial chylomicronemia syndrome (FCS).